JACC:单用替卡格雷对伴有糖尿病PCI患者的影响

2020-05-18 MedSci原创 MedSci原创

经皮冠状动脉介入治疗(PCI)后,短暂的双抗血小板治疗后单用P2Y12抑制剂替卡格雷可以减少出血,而不会增加缺血损伤。然而,这种方法对伴有糖尿病患者的影响尚不清楚。本研究的目的旨在比较和评估替卡格雷和

经皮冠状动脉介入治疗(PCI)后,短暂的双抗血小板治疗后单用P2Y12抑制剂替卡格雷可以减少出血,而不会增加缺血损伤。然而,这种方法对伴有糖尿病患者的影响尚不清楚。本研究的目的旨在比较和评估替卡格雷和替卡格雷联合阿司匹林对伴有糖尿病的PCI患者的影响。

本研究纳入分析的是2620名TWILIGHT临床研究中的糖尿病患者,主要终点是出血学术研究联合会2,3,或5出血,复合缺血终点为全因死亡、心肌梗死或中风。分析结果显示,出血发生率在替卡格雷组中要低于替卡格雷联合阿司匹林组(HR:0.65; 95% cl: 0.47-0.91; p = 0.012),而缺血事件的发生率在两组中无明显差异。在整个试验人群中,糖尿病状态和治疗组在原发性出血或缺血终点之间没有明显的相互关系。

研究结果显示,对于伴有糖尿病的PCI患者,与替卡格雷联合阿司匹林相比,单独替卡格雷治疗可以降低患者出血风险且不增加缺血风险。

原始出处:

Dominick J et al.Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.JACC.2020 May.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786815, encodeId=352b1e86815bd, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Mon Oct 26 01:25:02 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854773, encodeId=871d1854e73d8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Dec 06 10:25:02 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326619, encodeId=7647132661968, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 20 00:25:02 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370712, encodeId=eb8613e0712d8, content=<a href='/topic/show?id=691a603409f' target=_blank style='color:#2F92EE;'>#替卡格雷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60340, encryptionId=691a603409f, topicName=替卡格雷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Wed May 20 00:25:02 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043124, encodeId=491c10431244d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon May 18 12:25:02 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-10-26 zhmscau
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786815, encodeId=352b1e86815bd, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Mon Oct 26 01:25:02 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854773, encodeId=871d1854e73d8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Dec 06 10:25:02 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326619, encodeId=7647132661968, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 20 00:25:02 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370712, encodeId=eb8613e0712d8, content=<a href='/topic/show?id=691a603409f' target=_blank style='color:#2F92EE;'>#替卡格雷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60340, encryptionId=691a603409f, topicName=替卡格雷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Wed May 20 00:25:02 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043124, encodeId=491c10431244d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon May 18 12:25:02 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-12-06 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786815, encodeId=352b1e86815bd, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Mon Oct 26 01:25:02 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854773, encodeId=871d1854e73d8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Dec 06 10:25:02 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326619, encodeId=7647132661968, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 20 00:25:02 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370712, encodeId=eb8613e0712d8, content=<a href='/topic/show?id=691a603409f' target=_blank style='color:#2F92EE;'>#替卡格雷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60340, encryptionId=691a603409f, topicName=替卡格雷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Wed May 20 00:25:02 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043124, encodeId=491c10431244d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon May 18 12:25:02 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-05-20 docwu2019
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786815, encodeId=352b1e86815bd, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Mon Oct 26 01:25:02 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854773, encodeId=871d1854e73d8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Dec 06 10:25:02 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326619, encodeId=7647132661968, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 20 00:25:02 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370712, encodeId=eb8613e0712d8, content=<a href='/topic/show?id=691a603409f' target=_blank style='color:#2F92EE;'>#替卡格雷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60340, encryptionId=691a603409f, topicName=替卡格雷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Wed May 20 00:25:02 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043124, encodeId=491c10431244d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon May 18 12:25:02 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1786815, encodeId=352b1e86815bd, content=<a href='/topic/show?id=f762138395a' target=_blank style='color:#2F92EE;'>#PCI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13839, encryptionId=f762138395a, topicName=PCI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Mon Oct 26 01:25:02 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854773, encodeId=871d1854e73d8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Dec 06 10:25:02 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326619, encodeId=7647132661968, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed May 20 00:25:02 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370712, encodeId=eb8613e0712d8, content=<a href='/topic/show?id=691a603409f' target=_blank style='color:#2F92EE;'>#替卡格雷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60340, encryptionId=691a603409f, topicName=替卡格雷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Wed May 20 00:25:02 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043124, encodeId=491c10431244d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon May 18 12:25:02 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-05-18 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

IJIR:阴茎假体术后疼痛在糖尿病患者中更严重么?

充气阴茎假体(IPP)手术是药物难治性阴茎勃起功能障碍患者的一种有效、安全和令人满意的治疗选择。术后并发症包括感染、机械故障、侵蚀和疼痛。目前的文献表明需要一种更好的IPP术后疼痛治疗方法。

Sci Adv:1型糖尿病相关病毒的疫苗在动物模型中试验成功

导言:柯萨奇病毒B(CVBs)是人类常见的单链RNA病毒。在美国2014年至2016年间,CVB感染占报告肠道病毒病例的近10%。CVBs由六种血清型CVB1-6组成,在大多数情况下,这些病毒的感染是

初创公司Kriya获得8050万美元的A轮融资,开发糖尿病和严重肥胖症的基因疗法

Kriya的最初产品线包括多种基于AAV的基因疗法,用于治疗包括1型糖尿病、2型糖尿病和严重肥胖症在内的代谢疾病。

CELL METAB:“神药”二甲双胍减轻衰老相关炎症反应

衰老是年龄相关疾病伴随的炎症的一个不可改变的危险因素;因此,抗炎药有希望可以延长健康寿命。

糖尿病遇上忙碌的工作节奏怎么办?这个优选方案值得拥有!

患者,王先生,46岁,审计师。口干、乏力7年,加重伴多尿半月。

BMJ:青少年时期体重指数对晚年心血管、糖尿病及肿瘤风险的影响

青少年时期体重指数较高或与较低的乳腺癌风险相关